The Effect of Aspirin on Recurrent Acute Pancreatitis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age14-80
SponsorAir Force Military Medical University, China

About this trial

Recurrent acute pancreatitis (RAP) was defined as two or more occurrences of acute pancreatitis, which was associated with higher percentages of morbidities and mortalities, lower patients' life quality and increased health-care costs. Current interventions, including cholecystectomy and abstain from drinking were reported to be effective methods for preventing the recurrences of biliary and alcoholic etiologies, respectively. However, there were no effective preventions for other etiologies, such as idiopathic etiologies. Non-steroid anti-inflammatory drugs (NSAIDs), including indomethacin, diclofenac and aspirin could inhibiting the inflammatory cascade of pancreatitis. In this study, we aimed at exploring the effects of 100mg aspirin on reducing the occurrences of recurrent acute pancreatitis.

Eligibility criteria

Qualifiers

Patients with with recurrent acute pancreatitis

Disqualifiers

Less than 2 episodes of acute pancreatitis in the past year

Latrogenic AP (pancreatitis due to endoscopic retrograde cholangiopancreatography, surgery, or after other invasive treatment). Iatrogenic pancreatitis will not count as an episode of recurrent pancreatitis

Previous allergy to Non-Steroid Anti-inflammatory Drugs (NSAIDs)

Regularly taking aspirin or other NSAIDs >3 doses per week

Trial design

Treatments tested in this trial

  • 100mg aspirin

Treatment groups

23 Participants
are divided into 1 treatment group